Switzerland

Industry sources state it directly: ein Mehrbesitz- oder Fremdbesitzverbot existiert in der Schweiz nicht. Ownership and licensing are cantonal, but the corporate-chain model dominates retail. pharmaSuisse figures put roughly 57% of pharmacies in group ownership and 29% in chains, leaving under 14% independent.

No per-owner cap was found in any canton despite targeted searching. Treat that as not found rather than confirmed absent.

The real cantonal variation is not ownership but Selbstdispensation, physician self-dispensing. Seventeen of nineteen German-speaking cantons permit doctors to dispense directly from the practice, with Lucerne and Thurgau classical self-dispensing cantons and Aargau a prescription canton. French-speaking cantons are generally prescription-only. That determines whether a patient can get medication the same day from the prescriber or needs a separate pharmacy.

Wegovy entered the Spezialitätenliste on 1 March 2024: BMI 35 or above, or 28 to under 35 with a weight-related comorbidity. Prescribing is restricted to Endokrinologie and Diabetologie FMH specialists or accredited obesity centres with at least 300 patients a year. Stop at 16 weeks if weight loss is under 5% (BMI 28 to 35) or 7% (BMI 35 plus), with a further check at ten months. CHF 149.46 ex-factory, CHF 188.15 at pharmacy. The adult limitation expires 28 February 2027; an adolescent extension from 1 May 2025 expires 30 April 2028.

Mounjaro was extended to the weight-management indication effective 1 January 2026 by a Limitationsänderung. Same BMI criteria. Stop at 16 weeks on the same thresholds, again at ten months if cumulative loss is under 10% or 12%, and a hard three-year maximum treatment duration. Prescriber gating adds a volume threshold of 100 patients a year for individual specialists and 300 for centres, plus a required network of dietitian, psychologist, physiotherapist and bariatric-centre link. Pharmacy price CHF 223.82 (2.5 and 5mg), CHF 303.26 (7.5 and 10mg), CHF 388.40 (12.5 and 15mg). The limitation expires 31 December 2027.

That specialist gating is itself a structural barrier to a pure-telehealth model for the reimbursed segment. Self-pay is unrestricted.

This overturns the usual assumption. In January 2025 Swissmedic took action against Ringier, NZZ and 20 Minuten over ordinary journalistic coverage of Wegovy, Ozempic and Mounjaro, on the theory that even mere information about application possibilities constitutes advertising if it is designed and suitable to influence consumption behaviour. It reviewed 1,350 media mentions in 2024 and flagged a small number.

The dispute is unresolved. NZZ’s challenge to the takedown orders on weight-loss journalism is still pending before the Federal Administrative Court. A related NZZ case on a migraine article was decided against NZZ in May 2025 and is on appeal to the Federal Supreme Court. Politicians across FDP, SVP and SP have criticised the interpretation; Swissmedic says its reading is supported by current jurisprudence and has announced no change.

No action against a commercial GLP-1 operator, as distinct from media outlets, was found.

Correction. An earlier version of this page named care.health as the domestic operator. That was wrong on two counts: care.health is primarily a preventive diagnostics business with twelve physical locations, where weight loss is one module among many and no dedicated landing page exists in its sitemap; and the operator that actually matters was missing entirely.

ViaSlim AG (CHE-202.708.921, Zürich, incorporated 10 May 2024) is the company to beat. Founded by physicians Gezim Dervishi and Norbert Niebuhr, live since late January 2025, with a Bern branch and practices in Zürich and Bern. It is the only operator in the market with all four of: a Swiss legal entity, named Swiss-licensed physicians using HIN secure mail, a national licensed distribution partner, and a working reimbursement pathway alongside self-pay.

That distribution partner is the scarce asset in this market. Redcare Pharmacy Switzerland runs an Online-Arzt-Service Adipositas whose external doctor partner is ViaSlim and whose dispensing arm is MediService AG (CHE-108.428.075, Zuchwil SO). Redcare stocks all five Wegovy presentations and promises delivery in one to two days with no Apothekertaxen, which removes the pharmacy margin from the patient bill. Whoever holds Swiss mail-order capacity with cold chain controls the economics here, and Redcare has already chosen its telemedicine partner. The realistic alternatives for an entrant are Zur Rose Suisse AG or DocMorris AG, both in Frauenfeld.

ViaSlim discloses 1,131+ patient registrations and has 38 Trustpilot reviews, so it is small. Funding is undisclosed. Its own Impressum cites the Bern branch register number against the Zurich AG. But the structure is the hardest thing in this market to replicate.

Because Swissmedic reads art. 32 HMG more broadly than any EU regulator, every Swiss operator has to choose between conversion and exposure, and the market splits cleanly down that line.

The ones that do not name the drug: ViaSlim says only modernste Medikamente and ärztlich verschriebene Wirkstoffe, and states the reason on the page: prescription medicines may not be mentioned before a medical evaluation. Yazen says moderne Abnehmmedikamente. care.health names nothing. These operators gate the molecule behind an assessment and pay for it in conversion.

The ones that do: DoktorABC publishes Wegovy at CHF 276.35 per pen at every dose and Mounjaro from CHF 360.54, with manufacturer attribution, on an ungated public page. Apomeds publishes Wegovy at CHF 178.23, the cheapest listed price in the market and roughly 35% below DoktorABC. Both name Mounjaro and Saxenda openly too.

Neither DoktorABC nor Apomeds has a Swiss legal entity. Apomeds contracts through Apo Global Limited, a UK company in Weybridge citing MHRA supervision, and ships prescription medicines across the border from unnamed partner pharmacies. On a plain reading of art. 32 plus Swissmedic's demonstrated appetite for enforcement against even journalism, this is the most exposed positioning in the market.

Correction to this page: DoktorABC was previously recorded at CHF 190 to 210 a month. The live price today is CHF 276.35 per pen.

Nobody serves Romandie or Ticino natively. French and Italian speakers get translated German-origin funnels. ViaSlim carries all four languages, DoktorABC has a French funnel, Yazen is German-only and says French and Italian are coming in 2026. There is no Suisse romande or Ticinese operator. In a market where roughly a quarter of the population is French-speaking and language is a trust signal in healthcare, that is the clearest gap on the board.

Medgate has not moved. Switzerland's largest telemedicine provider, with five registered entities, appears to have no obesity or GLP-1 programme at all. The natural incumbent has left the category open. Worth confirming directly before relying on it.

And a warning about who else ranks for these terms. DOCVi, at docvi.ch and formerly medvi.ch, has no Swiss commercial register entry, targets Ozempic, Wegovy and Mounjaro in its meta keywords, and sells not licensed pens but GLP-1 of your choice, 10 vials, described as a Forschungswirkstoff für fortgeschrittene metabolische Forschungsprotokolle, a research compound. It offers Retatrutide, approved nowhere, and a Single Purchase tier with no questionnaire, no plan, no recurring commitment. That maps almost exactly onto what Swissmedic warned about on 26 August 2025. It is not a competitor; it is a liability for the category, and it makes regulators more suspicious of every legitimate digital operator.

Because Switzerland sits outside the EU and EMA system, the European Commission’s July 2026 oral Wegovy authorisation does not apply. A separate Swissmedic authorisation is required and was still pending as of the most recent sources. Swissmedic is reported to be actively reviewing orforglipron. This is a Switzerland-specific gap against every EU market.

On enforcement, Swissmedic warned on 26 August 2025 about fake and misleading GLP-1 products, including an injectable marketed as purely natural that lab work confirmed contained therapeutic-dose semaglutide, and criminal relabelling of insulin pens as GLP-1 products. On 22 June 2026 a cross-agency operation with customs and Swiss Sport Integrity inspected 46 suspicious peptide shipments and retained 23, about 80% originating from Poland.